Title: Ventilator-Associated Pneumonia: The Effect of Bacterial Resistance
Authors: Yousry Elsaeed Risk, Mohamed Abd Elmohsen Elmahdy, Ahmed Hamdy Abd Elrahman, Bassem Mefreh Aglan, Mohamed Ossama Mohamed Abd Elsadek
DOI: https://dx.doi.org/10.18535/jmscr/v7i7.42
Abstract
Background: there have been many study in preventing ventilator-associated pneumonia (VAP), Although it VAP remains the most diffuse Hospital aquired infection in intensive care units (ICU)(1). VAP worse patient recovery and increasing length of hospitalization, duration of mechanical ventilation, and hospitalization costs.(2)
Moreover, VAP is lead to increase mortality rates (14–70%), due to resistant bacteria, inappropriate antimicrobial therapy use, and incorrect antimicrobial prescription or de-escalation therapy.(3, 4)
Patients and Methods: This study was done on 40 patients in ICU at Benha University Hospital in the period from august 2017 to march 2019. who were put on mechanical ventilation and diagnosed to have VAP.19 patients died in our study and 21 patients were discharged alive.
Results: This study observed that error in maintenance dose treatment, error in treatment duration and delay in starting antimicrobial therapy followed by the interval between doses, error in loading dose and inappropriate adjustment for renal function. were found increased in patients who died. de-escalation therapy compared to maintenance therapy lead to low mortality rates and higher mortality rates in older patients with more comorbidities..
Keywords: ventilator-associated pneumonia; mechanical ventilation; antimicrobial prescription.
References
- Rocha Lde A, Vilela CA, Cezário RC, Almeida AB,. Ventilator-associated pneumonia in an adult clinical–surgical intensive care unit of Brazilian university hospital: incidence, risk factors, etiology, and antibiotic resistance. Braz J Infect Dis. 2018; 12:80–5.
- Hayashi Y, Morisawa K, et al. Toward improved surveillance: the impact of ventilator associated complications on length of stay and antibiotic use in patients in intensive care units. Clin Infect Dis. 2013; 56: 471–7.
- Teixeira PJZ, Hertz FTP, Cruz DB, MoreiraJS. Pneumonia associada à ventilac¸ ãomecânica: impactoda multir resistência bacterianana morbidade e mortalidade. J Br as Pneumol. 2014; 30:540–8.
- Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator associated pneumonia. Crit Care Med. 2004; 32:2183–90.
- Chung DR, Song JH, et al. High prevalence of multidrug-resistant non fermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011; 184:1409–17.
- Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006; 5:1210–8.7
- American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator -associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
- Gilbert DN, Chambers HF, Eliopoulos GM, Michael SS. The Sanford guide to antimicrobial therapy. Sperryville: Copyright; 2014.10.
- Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2012; 41:582–637.